Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of each VRC01 dose in preventing HIV infection. For t...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Yunda Huang, Shelly Karuna, Lindsay N. Carpp, Daniel Reeves, Amarendra Pegu, Kelly Seaton, Kenneth Mayer, Joshua Schiffer, John Mascola, Peter B. Gilbert
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2018-09-01
Serier:	Human Vaccines & Immunotherapeutics
Fag:	antibody mediated prevention trial broadly neutralizing antibody non-human primate challenge study population pharmacokinetics statistical modeling of hiv prevention efficacy vrc01
Online adgang:	http://dx.doi.org/10.1080/21645515.2018.1462640
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!